Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-κB and HSP27/p38/AKT Pathways and by Inhibiting ABCB1

por Sims, Jonathan T., Ganguly, Sourik S., Bennett, Holly, Friend, J. Woodrow, Tepe, Jessica, Plattner, Rina
Publicado 2013